BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26193636)

  • 1. Med12 gain-of-function mutation causes leiomyomas and genomic instability.
    Mittal P; Shin YH; Yatsenko SA; Castro CA; Surti U; Rajkovic A
    J Clin Invest; 2015 Aug; 125(8):3280-4. PubMed ID: 26193636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
    Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
    Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
    Croce S; Chibon F
    Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
    Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
    Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
    Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
    Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
    Di Tommaso S; Tinelli A; Malvasi A; Massari S
    Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
    Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
    Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
    Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
    Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
    Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
    Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
    Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
    Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
    Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
    Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
    Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
    Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
    Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
    Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
    Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
    Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
    Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
    JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mediator complex subunit 12 gain-of-function mutation induces partial leiomyoma cell properties in human uterine smooth muscle cells.
    Takao T; Ono M; Yoshimasa Y; Masuda H; Maruyama T
    F S Sci; 2022 Aug; 3(3):288-298. PubMed ID: 35643626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
    Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
    Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
    Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
    J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.